One of the primary challenges is the immunosuppressive TME inherent to solid tumors such as CRC.67-69 The CRC microenvironment contains various immunosuppressive cells, such as regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages, which can inhibit CAR-T cell function and proliferation.70,71 Additionally, CRC tumors often secrete immunosuppressive cytokines such as transforming growth factor-β and IL-10, further dampening the immune response and reducing the effectiveness of CAR-T cell therapy.72,73. This evidence concerns the gene IL10 and colorectal carcinoma.